Verasonics

Executive Summary

Verasonics is a leading provider of programmable research ultrasound systems, headquartered in Kirkland, WA. Founded in 2001, the company's Vantage and Vantage NXT platforms enable researchers to acquire raw channel data with unmatched hardware fidelity and software flexibility, serving as a critical tool for academic, institutional, and commercial R&D in ultrasound imaging, therapy, and materials science. With over two decades of market presence, Verasonics has established itself as a foundational technology provider for the ultrasound research community, powering innovations from novel imaging techniques to therapeutic ultrasound applications. Despite being private and operating at the research tool level, the company is well-positioned to benefit from the growing demand for non-invasive diagnostics and targeted therapies. However, the lack of publicly disclosed financial performance or clinical-stage products limits visibility into near-term commercial traction.

Upcoming Catalysts (preview)

• Q4 2026Next-generation Vantage platform launch75% success
• H1 2027Strategic partnership with an OEM for clinical ultrasound integration40% success
• Q2 2026Expansion into neuromodulation research applications60% success